Skip to main content

Table 2 Baseline characteristics of the patients according to the optimal cut-off value of the TyG index

From: A synergistic effect of the triglyceride-glucose index and the residual SYNTAX score on the prediction of intermediate-term major adverse cardiac events in patients with type 2 diabetes mellitus undergoing percutaneous coronary intervention

Variable

the Tyg index ≤ 9.04 (n = 315)

the Tyg index > 9.04 (n = 318)

P value

Age, years

69.31 ± 10.54

66.75 ± 10.81

0.003

Female

101 (32.1)

1.7 (33.6)

0.671

BMI, kg/m2

24.60 ± 2.93

25.19 ± 3.24

0.016

Smoking, n (%)

136 (43.2)

148 (46.5)

0.395

Previous PCI, n (%)

35 (11.1)

33 (10.4)

0.766

COPD, n (%)

15 (4.8)

13 (4.1)

0.680

Hypertension, n (%)

234 (74.3)

243 (76.4)

0.534

AF, n (%)

21 (6.7)

31 (9.7)

0.158

Previous Stroke, n (%)

18 (5.7)

18 (5.7)

0.977

SBP, mmHg

133.36 ± 22.64

133.96 ± 21.30

0.731

HR, bpm

77.43 ± 13.92

80.12 ± 15.69

0.023

cTnT, pg/ml

26.80 (13.50, 408.80)

38.84 (13.33, 604.93)

0.170

BNP, pg/ml

92.80 (39.20, 294.00)

130.00 (44.63, 462.81)

0.065

Scr (umol/L)

79.00 (67.00, 96.20)

76.10 (63.00, 100.98)

0.614

FBG (mmol/L)

7.08 ± 2.10

9.67 ± 3.29

 < 0.001

HbA1c

7.26 ± 1.61

7.93 ± 1.76

 < 0.001

TG (mmol/L)

1.11 ± 0.33

2.01 ± 1.02

 < 0.001

TC (mmol/L)

4.10 ± 1.16

4.67 ± 1.31

 < 0.001

HDL-C (mmol/L)

1.13 ± 0.30

1.12 ± 0.29

0.466

LDL-C (mmol/L)

2.47 ± 0.80

2.86 ± 0.93

 < 0.001

LVEF

55.04 ± 9.50

55.11 ± 9.90

0.226

AMI, n (%)

130 (41.3)

154 (48.4)

0.070

Diagnosis,n (%)

  

0.150

CCS

52 (16.5)

38 (11.9)

 

UA

133 (42.2)

126 (39.6)

 

NSTEMI

70 (22.2)

74 (23.3)

 

STEMI

60 (19.0)

80 (25.2)

 

Aspirin, n (%)

309 (98.1)

304 (95.6)

0.072

P2Y12 receptor inhibitor, n (%)

313 (99.4)

313 (98.4)

0.259

Statins, n (%)

307 (97.5)

311 (97.8)

0.780

β-blockers, n (%)

214 (67.9)

238 (74.8)

0.055

ACEI/ARB, n (%)

151 (47.9)

169 (53.1)

0.190

Diuretics, n (%)

62 (19.7)

77 (24.2)

0.169

Insulin, n (%)

74 (23.5)

93 (29.2)

0.101

Oral hypoglycemic agents, n (%)

220 (69.8)

230 (72.3)

0.490

MVD, n (%)

227 (72.1)

246 (77.4)

0.125

LM, n (%)

24 (7.6)

21 (6.6)

0.619

Calcified lesions, n (%)

58 (18.4)

61 (19.2)

0.804

Thrombosis, n (%)

28 (8.9)

30 (9.4)

0.812

Long lesion, n (%)

193 (61.3)

203 (63.8)

0.504

CTO, n (%)

62 (19.7)

77 (24.2)

0.169

Number of stents

1.55 ± 0.94

1.53 ± 0.94

0.780

Length of stents, mm

40.54 ± 27.65

41.09 ± 28.50

0.805

Tyg index

8.65 ± 0.33

9.50 ± 0.40

 < 0.001

bSS

15.00 (9.00,21.00)

15.75 (9.00,21.50)

0.458

rSS

4.00 (0.00,8.00)

4.25 (1.00,9.00)

0.327

  1. The groups were stratified by the optimal cutoff value of the TyG index to measure MACEs, which was determined by receiver‑operating characteristic curve analysis. Data are presented as mean ± SD, median (IQR) or n (%)
  2. MACEs major adverse cardiac events, BMI body mass index, PCI percutaneous coronary intervention, COPD chronic obstructive pulmonary disease, AF atrial fibrillation, SBP systolic blood pressure, HR heart rate, BNP brain natriuretic peptide, Scr serum creatinine, FBG fasting blood glucose, TG triglyceride, TC total cholesterol, HDL high density lipoprotein, LDL low density lipoprotein, LVEF left ventricular ejection fraction, AMI acute myocardial infarction, CCS chronic coronary syndrome, UA unstable angina, STEMI ST-segment elevation myocardial infarction, NSTEMI non-ST-segment elevation myocardial infarction, ACEI/ARB angiotensin converting enzyme inhibitor/angiotensin receptor blocker, MVD multivessel disease, LM left main disease, CTO chronic total occlusion, TyG index the triglyceride–glucose index, bSS baseline SYNTAX score, rSS residual SYNTAX score.
Back to article page

Cardiovascular Diabetology

ISSN: 1475-2840